Document is current
Any future updates will be listed below
-
Authors
Lee, Jong Geol https://orcid.org/0000-0002-4312-6282
Yon, Jung-Min
Kim, Globinna
Lee, Seul-Gi
Kim, C-Yoon
Cheong, Seung-A
Kim, Hyun-Yi
Yu, Jiyoung
Kim, Kyunggon
Sung, Young Hoon https://orcid.org/0000-0002-1508-9883
Yoo, Hyun Ju https://orcid.org/0000-0003-2617-444X
Woo, Dong-Cheol
Rho, Jin Kyung https://orcid.org/0000-0003-3918-0099
Ha, Chang Hoon https://orcid.org/0000-0001-7606-4340
Pack, Chan-Gi https://orcid.org/0000-0002-6578-3099
Oh, Seak Hee
Lim, Joon Seo
Han, Yu Mi
Hong, Eui-Ju
Seong, Je Kyung https://orcid.org/0000-0003-1177-6958
Lee, Han-Woong https://orcid.org/0000-0001-9515-3605
Lee, Sang-Wook
Lee, Ki-Up
Kim, Chong Jai
Nam, Sang-Yoon
Cho, You Sook https://orcid.org/0000-0001-8767-2667
Baek, In-Jeoung https://orcid.org/0000-0002-0641-7208
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2020R1A2C2012912, 2018M3A9D5A01087977)
Asan Institute for Life Sciences, Asan Medical Center (2020-028, 2022-013, 2023-062)
- License Information
-
More Information
Article History
Received: 9 June 2023
Accepted: 30 January 2024
First Online: 19 February 2024
Competing interests
: J.G.L., J.-M.Y., K.K., Y.S.C., and I.-J.B. have filed a provisional patent application in the Korea patent office (composition for preventing and treating pregnant complications related to placenta and/or fetal cardiovascular abnormalities by targeting PIBF1). All the other authors declare no competing interests.
: HUVEC preparation was approved by the Institutional Review Board of the Asan Medical Center (approval ID: 2022-0664). Written informed consent was obtained from all participants or their families in accordance with the Declaration of Helsinki.
